Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 13/20 | 0.52 |
| ▸ | HSD17B2 | P37059 | 12/20 | 0.52 |
| ▸ | METAP2 | P50579 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4049981 | 0.80 | KMO (0.40) | — | |
| SCHEMBL2093090 | 0.79 | IDO1 (0.49) | CDC7CDK2ESR2 | |
| SCHEMBL4047528 | 0.77 | MAPT (0.43) | HSD17B1HSD17B2CDC7ESR1ESR2 | |
| SCHEMBL63014 | 0.77 | RAB9A (0.41) | METAP2CYP1A2 | |
| SCHEMBL4047707 | 0.73 | AKT1 (0.42) | METAP2CYP3A4CYP1A2 | |
| SCHEMBL6002382 | 0.71 | ALDH1A1 (0.36) | — | |
| SCHEMBL4047980 | 0.71 | DRD1 (0.44) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL4051854 | 0.71 | ASIC3 (0.46) | CYP3A4CYP1A2 | |
| SCHEMBL30862097 | 0.70 | HSD17B1 (0.66) | HSD17B1HSD17B2METAP2CYP3A4CYP2C9 | |
| SCHEMBL6002991 | 0.69 | XDH (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589096-B2 | Azole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-15 | — | — | US | disclosed |
| EP-1566384-B1 | NOVEL AZOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2009-06-17 | — | — | EP | disclosed |
| US-20080188507-A1 | Novel azole derivatives | MSD K.K. (JP) | 2008-08-07 | — | — | US | disclosed |
| US-7365079-B2 | Azole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-29 | — | — | US | disclosed |
| US-20060111380-A1 | Novel azole derivatives | MSD K.K. (JP) | 2006-05-25 | — | — | US | disclosed |
| EP-1566384-A1 | NOVEL AZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188507-A1 | Novel azole derivatives | NPY1R, NPY5R, NPY2R | HSD17B1 1461/4885HSD17B2 1397/4885METAP2 1229/4885 |
| US-20060111380-A1 | Novel azole derivatives | NPY1R, NPY5R, NPY2R | HSD17B1 1225/4885HSD17B2 1168/4885METAP2 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.